Skip to main content
BAX
NYSE Life Sciences

EU Regulator Warns of Prolonged Shortage for Baxter's Key Cancer Drug Until Early 2027

Tom Rudovsky · Reported by Reuters
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$16.41
Mkt Cap
$8.443B
52W Low
$16.08
52W High
$34.515
52W Position info
2.1% above low
Off High info
52% below high
Rel. Volume
Market data snapshot near publication time

BAX is trading near its 52-week low of $16.08 (2.1% above the low).

Summary

The European Union's medicines regulator has issued a warning that Baxter International's cancer treatment containing ifosfamide will face a prolonged shortage across the bloc until early 2027. This significant disruption stems from a technical issue at a contract manufacturing site, impacting a critical product for which Baxter is the primary EU supplier. This development adds to a challenging period for Baxter, which recently reported a net loss, substantial impairments, and product recalls in its last 10-K, and follows a prior warning regarding a shortage of another cancer drug, cyclophosphamide. The extended unavailability of a key pharmaceutical product is expected to negatively impact the company's revenue, market share, and reputation, further pressuring a stock already trading near its 52-week low. Traders will be closely monitoring updates on manufacturing resolution and any potential revisions to financial guidance.

At the time of this announcement, BAX was trading at $16.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $16.08 to $34.52. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $25.43 info
Change: +$2.49 (+11%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 8:06 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $25.43 info
Change: -$0.570 (-2%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.74
Real-time Price: $25.43 info
Change: -$1.31 (-5%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.50
Real-time Price: $25.43 info
Change: -$1.07 (-4%) info
Market Cap: $13.135B info
BAX
Aug 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.20
Real-time Price: $25.43 info
Change: -$0.770 (-3%) info
Market Cap: $13.135B info